Acupuncture and Related Therapies for the Anxiety and Depression in Irritable Bowel Syndrome with Diarrhea (IBS-D): A Network Meta-analysis of Randomized Controlled Trials

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2023 Jan 9

PMID 36620677

Authors

Xuesong Wang

Xuliang Shi

Jing Lv

Juncha Zhang

Yongli Huo

Guang Zuo

Guangtong Lu

Cunzhi Liu

Yanfen She

Affiliations

Soon will be listed here.

Abstract

Objective: A growing number of clinical studies have suggested the value of acupuncture-related therapies for patients with irritable bowel syndrome with diarrhea (IBS-D), and the patient's mental state plays an important role, but there are many types of acupuncture-related therapies involved. This study aimed to evaluate the mental status, efficacy and safety of the different acupuncture-related therapies for IBS-D patients.

Methods: We searched seven databases to collect randomized controlled trials of acupuncture-related therapies for IBS-D. After independent literature screening and data extraction, the quality of the final included literature was evaluated. Hamilton anxiety rating scale (HAMA), hamilton depression rating scale (HAMD), self-rating anxiety scale (SAS), and self-rating depression scale (SDS) was used as the primary outcome indicator. And the network meta-analysis (NMA) was performed by using Revman 5.4, Stata 15.0 and WinBUGS 1.4.3 software, and the surface under the cumulative ranking curve was conducted to rank the included interventions.

Results: We analyzed 24 eligible studies with 1,885 patients, involving eight types of acupuncture and related therapies along with comprehensive therapies. The NMA result shows that: for SAS scores, combined therapies were more efficacious than anti-diarrheal or antispasmodic (western medicine, WM) (SMD: -8.92; 95% CI: -15.30, -2.47); for SDS scores, combined therapies were more efficacious than WM (SMD: -8.45; 95% CI: -15.50, -1.41). For HAMA scores, moxibustion (MOX) was more efficacious than placebo (SMD: -8.66; 95% CI: -16.64, -0.38). For HAMD scores, MOX was more efficacious than all other included interventions. For response rate, MOX was more efficacious than the following interventions: acupuncture (ACU) (SMD:0.29; 95% CI:0.08,0.93), Chinese herb medicine (CH) (SMD:0.09; 95% CI:0.02,0.36), combined therapies (SMD:0.23; 95% CI:0.06, 0.85), electroacupuncture (EA) (SMD:0.06; 95% CI:0.01,0.33), warm acupuncture (WA) (SMD:22.16; 95% CI:3.53,148.10), WM (SMD:15.59; 95% CI:4.68,61.21), and placebo (SMD:9.80; 95% CI:2.90,45.51). Combined therapies were more efficacious than the following interventions: CH (SMD:0.39; 95% CI:0.19,0.80), WA (SMD:4.96; 95% CI:1.30,21.62), and WM (SMD:3.62; 95% CI:2.35,5.66). The comprehensive ranking results show that MOX, ACU, combined therapies, and EA had high SUCRA rankings involving different outcome indicators.

Conclusion: MOX, ACU, combined therapies, and EA better alleviate anxiety and depression among IBS-D patients, and with a higher safety level, may be the optimal therapies. In addition, combining acupuncture-related treatments and other therapies also delivers a higher global benefit level.

Systematic Review Registration: [https://www.crd.york.ac.uk/], identifier [CRD42022364560].

Citing Articles

The effect of acupuncture on quality of life in patients with irritable bowel syndrome: A systematic review and meta-analysis.

Zhou J, Lamichhane N, Xu Z, Wang J, Quynh V, Huang J PLoS One. 2025; 20(2):e0314678.

PMID: 39946356 PMC: 11824959. DOI: 10.1371/journal.pone.0314678.

Self-administered active versus sham acupressure for diarrhea predominant irritable bowel syndrome: a nurse-led randomized clinical trial.

Asal M, El-Sayed A, Alsenany S, Ramzy Z, Dawood R BMC Nurs. 2025; 24(1):106.

PMID: 39875940 PMC: 11776273. DOI: 10.1186/s12912-024-02594-5.

Effect of Shengyang Yiwei Decoction combined with selective serotonin reuptake inhibitor antidepressants on HAMD-17 score and somatic symptoms in patients with depression.

Li L, Wan A, Zhao M, Yu L, Han Y, Mi K Pak J Med Sci. 2025; 41(1):205-209.

PMID: 39867783 PMC: 11755288. DOI: 10.12669/pjms.41.1.9835.

Efficacy of acupuncture in refractory irritable bowel syndrome patients: a randomized controlled trial.

Zhao J, Zheng H, Wang X, Wang X, Shi Y, Xie C Front Med. 2024; 18(4):678-689.

PMID: 38958923 DOI: 10.1007/s11684-024-1073-7.

Neural circuit mechanisms of acupuncture effect: where are we now?.

Wang X, Wang J, Han R, Yu C, Shen F Front Neurol. 2024; 15:1399925.

PMID: 38938783 PMC: 11208484. DOI: 10.3389/fneur.2024.1399925.

References

Ohman L, Simren M . Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010; 7(3):163-73. DOI: 10.1038/nrgastro.2010.4. View

Camilleri M, Boeckxstaens G . Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017; 66(5):966-974. DOI: 10.1136/gutjnl-2016-313425. View

Zhang Z, Chen H, Yip K, Ng R, Taam Wong V . The effectiveness and safety of acupuncture therapy in depressive disorders: systematic review and meta-analysis. J Affect Disord. 2009; 124(1-2):9-21. DOI: 10.1016/j.jad.2009.07.005. View

Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z . Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019; 19(1):208. PMC: 6689876. DOI: 10.1186/s12906-019-2624-3. View

Koloski N, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley N . The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012; 61(9):1284-90. DOI: 10.1136/gutjnl-2011-300474. View

Kabra N, Nadkarni A . Prevalence of depression and anxiety in irritable bowel syndrome: A clinic based study from India. Indian J Psychiatry. 2013; 55(1):77-80. PMC: 3574461. DOI: 10.4103/0019-5545.105520. View

Armour M, Smith C, Wang L, Naidoo D, Yang G, MacPherson H . Acupuncture for Depression: A Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(8). PMC: 6722678. DOI: 10.3390/jcm8081140. View

Sun Y, Wang S, Yu T . [ acupuncture method combined with electroacupuncture for diarrhea-type irritable bowel syndrome : a randomized controlled trial]. Zhongguo Zhen Jiu. 2021; 41(1):13-6. DOI: 10.13703/j.0255-2930.20191220-k0001. View

Bao C, Wu L, Shi Y, Shi Z, Jin X, Shen J . Long-term effect of moxibustion on irritable bowel syndrome with diarrhea: a randomized clinical trial. Therap Adv Gastroenterol. 2022; 15:17562848221075131. PMC: 8874177. DOI: 10.1177/17562848221075131. View

10.

Chen Y, Chen X, Yin X . [Comparison of the therapeutic effects of electroacupuncture and probiotics combined with deanxit in treating diarrhea-predominant irritable bowel syndrome]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012; 32(5):594-8. View

11.

Wong Y, Wu J, Zhou G, Zhu F, Zhang Q, Yang X . Antidepressant Monotherapy and Combination Therapy with Acupuncture in Depressed Patients: A Resting-State Functional Near-Infrared Spectroscopy (fNIRS) Study. Neurotherapeutics. 2021; 18(4):2651-2663. PMC: 8804104. DOI: 10.1007/s13311-021-01098-3. View

12.

Carroll I, Ringel-Kulka T, Keku T, Chang Y, Packey C, Sartor R . Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011; 301(5):G799-807. PMC: 3220325. DOI: 10.1152/ajpgi.00154.2011. View

13.

Badia X, Mearin F, Balboa A, Baro E, Caldwell E, Cucala M . Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics. 2002; 20(11):749-58. DOI: 10.2165/00019053-200220110-00004. View

14.

Lovell R, Ford A . Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7):712-721.e4. DOI: 10.1016/j.cgh.2012.02.029. View

15.

Wang X, Li J, Wang Y, Yu C, He C, Huang Z . Acupuncture and Related Therapies for the Cognitive Function of Alzheimer's Disease: A Network Meta-Analysis. Iran J Public Health. 2022; 50(12):2411-2426. PMC: 9577142. DOI: 10.18502/ijph.v50i12.7924. View

16.

Greenwood-Van Meerveld B, Prusator D, Johnson A . Animal models of gastrointestinal and liver diseases. Animal models of visceral pain: pathophysiology, translational relevance, and challenges. Am J Physiol Gastrointest Liver Physiol. 2015; 308(11):G885-903. DOI: 10.1152/ajpgi.00463.2014. View

17.

Barberio B, Houghton L, Yiannakou Y, Savarino E, Black C, Ford A . Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. Am J Gastroenterol. 2020; 116(2):362-371. DOI: 10.14309/ajg.0000000000000946. View

18.

Camilleri M, McKinzie S, Busciglio I, Low P, Sweetser S, Burton D . Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008; 6(7):772-81. PMC: 2495078. DOI: 10.1016/j.cgh.2008.02.060. View

19.

Drossman D, Dumitrascu D . Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006; 15(3):237-41. View

20.

Wang X, Shi X, Lv J, Zhang J, Huo Y, Zuo G . Acupuncture and related therapies for the anxiety and depression in irritable bowel syndrome with diarrhea (IBS-D): A network meta-analysis of randomized controlled trials. Front Psychiatry. 2023; 13:1067329. PMC: 9816906. DOI: 10.3389/fpsyt.2022.1067329. View